Bollywood's Gutkha Gauntlet: Tukaram Mundhe's FDA Takes on Shah Rukh, Ajay, and Tiger in the Vimal Elaichi Controversy

When Bollywood's brightest stars lend their faces to advertisements, it's usually a dazzling affair, full of glamour and aspirational messaging. But what happens when that star power gets tangled in a debate about public health and alleged surrogate advertising? That's precisely the knotty situation unfolding around the 'Vimal Elaichi' endorsements, bringing regulatory authorities face-to-face with industry titans like Shah Rukh Khan, Ajay Devgn, and Tiger Shroff. And frankly, it's a saga that even saw Akshay Kumar making a swift exit amidst considerable public outcry.

At the heart of this brewing storm is Tukaram Mundhe, the resolute Commissioner of the Maharashtra Food and Drug Administration (FDA). His office recently, on August 16, 2026, sent show-cause notices to Shah Rukh Khan, Ajay Devgn, and Tiger Shroff, demanding an explanation for their involvement in the Vimal Elaichi advertisements. You see, while 'elaichi' (cardamom) seems innocuous enough, the FDA's core contention is that these ads serve as a clever, albeit problematic, front for Vimal Pan Masala – a product explicitly banned for manufacture, storage, and sale in Maharashtra under the FSS Act 2006, effective from July 13, 2026.

The FDA’s argument is quite straightforward: the visual presentation, the brand name, and the overall market context of 'Vimal Elaichi' advertisements create an undeniable and direct association with the banned pan masala. It’s a classic case of alleged 'surrogate advertising,' where a legal product is advertised in a way that indirectly promotes a prohibited one. This, Mundhe and his team believe, misleads consumers and, perhaps more critically, circumvents vital public health regulations designed to protect people from products linked to adverse health outcomes. The notices, delivered to Shah Rukh Khan's residence in Bandra and Ajay Devgn's home in Juhu, highlight the seriousness with which the state agency views this matter.

It's worth noting that this isn't the first time Vimal has faced celebrity-related scrutiny. Cast your mind back to 2022, and you'll recall the significant public backlash against Akshay Kumar for his endorsement of Vimal Elaichi. Known for his image as a fitness advocate and someone who often promotes healthy living, Kumar’s association with a brand so closely linked to gutkha and tobacco products stirred a hornet's nest. He ultimately apologized and stepped down from the campaign, a clear indicator of the immense public pressure and the ethical tightrope celebrities walk when choosing their endorsements.

But the Vimal saga isn't just confined to Maharashtra's FDA. The brand is facing legal heat on multiple fronts. In Jaipur, for instance, a consumer forum has also stepped in. Advocate Yogendra Singh Badiyal filed a complaint alleging that Vimal Pan Masala advertisements misleadingly claim the presence of saffron, despite the price point making such an inclusion highly improbable. The District Consumer Disputes Redressal Commission, Jaipur II, comprising Chairman Gyarsilal Meena and member Hemlata Agarwal, has even issued notices to the actors involved and Vimal Kumar Agarwal, the chairman of JB Industries (the manufacturer), requiring their appearance on March 19.

Furthermore, the controversy has spread to other states. In Muzaffarpur, Bihar, activist Tamanna Hashmi filed a plea back in May 19, taking issue with actors generally promoting gutkha and tobacco products. All these actions underscore a growing public and regulatory intolerance for advertisements perceived to be pushing harmful substances, especially when fronted by beloved public figures.

The stakes, frankly speaking, are high for the celebrities and the company. Under the FSS Act 2006, misleading endorsements can attract hefty penalties, ranging from ₹10 lakh to a staggering ₹50 lakh. Moreover, offending endorsers could face a ban from brand promotions for up to three years. The matter has even been forwarded to the Food Safety and Standards Authority of India (FSSAI) and the Central Consumer Protection Authority (CCPA) for further action, signalling a coordinated effort across various regulatory bodies. This isn't just about a brand; it's about the broader responsibility of influence and the lines that should never be crossed, particularly when public health is at stake. The Vimal Elaichi controversy serves as a stark reminder that even the biggest stars aren't above the law or public accountability.